On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) held a strategic cooperation launch ceremony, announcing a partnership on the national retail market for Outangning® (Linagliptin). Starting from January 1, 2025, the distribution and promotion of Linagliptin in non – medical institution channels in China will be fully managed by Shanghai Pharmaceuticals Holding Co.
Partnership Details
The successful signing of this strategic cooperation marks the beginning of a new chapter in the partnership between Boehringer Ingelheim and Shanghai Pharmaceuticals. Looking ahead, the two companies will continue to deepen their cooperation, fully utilizing their respective product and resource advantages. Through innovative cooperation models, they aim to drive continuous development and jointly benefit a broader group of chronic disease patients. They will also support the improvement of the public health service system, optimize chronic disease health management, and work together to contribute to the realization of the “Healthy China 2030” goal.-Fineline Info & Tech
